ValiRx chief says company is at an exciting phase as it updates on two key cancer candidates
Chief executive, Dr Satu Vainikka, said she looked forward to the “successful crystallisation of substantial value for patients and shareholders"
Company
ValiRx PLC
LON:VAL
ValiRx is a drug development company, which focuses on the translation of scientific innovation into clinical candidates for cancer, related conditions and women’s health. The company's specialised business model connects science, finance and commerce to accelerate early-stage drug development. It identifies proprietary and novel drug candidates with the potential to improve patient lives, providing the expertise and investment required for optimised development and value creation.
310 stories · page 6 of 16
Investments and investor services
FTSE 100 closes lower again as traders flee from risk
The UK blue chip index was about 10 points lower at 7,373, above the session low of 7,357.09 but below the morning peak of 7,397.74
Investments and investor services
Mosman the top riser in London after production update
Companies featured: Anglo Asian Mining, CloudCall, Greatland Gold, Mosman Oil & Gas, NCC, ValiRx
Archive
Proactive news snapshot: Mosman Oil And Gas, ValiRx, Anglo Asian Mining, Clinigen Group …
A glance at some of the day's highlights from the Proactive Investors newswire
ValiRx advances as it wins patent protection pre-clinical drug to treat endometriosis
The gynaecological disorder occurs when tissue similar to the lining of the uterus, or endometrium, migrates outside of the womb, generally to the fallopian tubes, ovaries and tissue around the uterus
FTSE 100 closes higher as pound crashes amid Brexit worries
Footsie added nearly 26 points to stand at 7,626, while FTSE 250 also finished higher - up almost 71 points at 20,871
Valirx's talks in lung cancer highlight progress on all fronts
Valirx raised just short of a £1mln in May to progress the clinical trial of VAL201 and to advance the pre-clinical programmes, VAL101 and VAL301.
EQTEC surges on new €22mln contract win
Some of the main news-driven risers and fallers in London on Thursday afternoon...
Archive
Proactive news snapshot: UK Oil & Gas Investments, ValiRx, Kazera Global …
A glance at some of the day's highlights from the Proactive Investors newswire
ValiRx surges as it continues “advanced conversations” with possible partners for lung cancer drug
ValiRx released the positive results of a phase II trial of its lead drug earlier this year and it is now looking for a partner to help take VAL401 through a phase III study and into the market
ValiRx raises £0.95mln through a placing of 47.5mln new ordinary shares at 2.0p each
The firm said the funds will be used for progressing the clinical trial of VAL201 and for advancing the pre-clinical programmes, VAL101 and VAL301
Archive
Proactive news snapshot: ReNeuron Group, DP Poland, Minds + Machines …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Feedback, Futura Medical, Mosman Oil & Gas …
A glance at some of the day's highlights from the Proactive Investors newswire
Stellar Diamonds shares leap as court approves its acquisition by NWF
A look at some of the biggest risers and fallers in London on Wednesday
ValiRx receives EU patent grant for prostate cancer drug
The grant comes hot on the heels of a patent grant for the treatment in the US on 20 March
FTSE 100 pares losses as US bond yields rise above 3%
Resource stocks suffer as US dollar makes headway on forex markets
Archive
Proactive news snapshot: ValiRx, Stratex International, ANGLE …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
MyCelx ups full-year guidance as new order and equipment sale bring in US$2.7mln
MYCELX now expects full-year revenues to be in the range of US$16-17mln after the new order and equipment sale
ValiRx shoots higher, innovation effective at inducing programmed cell death in a wide range of cancers
The company is developing VAL101 in collaboration with academic and commercial partners in Finland, Germany and Denmark
FTSE 100 closes in the black as Shire surges; tobacco stocks drift lower
Shire shares ended 5.89% up as the group received and rejected a takeover approach from Japan's Takeda Pharma